| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 0.92 [0.88, 0.97] | | < 1 | | 35% | 109 studies (105/4) | 99.9 % | moderate | critical | moderate | crucial | - |
| death or transfer to ICU | 0.75 [0.62, 0.89] | | < 1 | | 69% | 15 studies (9/6) | 99.9 % | moderate | critical | moderate | crucial | - |
| deaths | 0.75 [0.69, 0.82] | | < 1 | | 92% | 283 studies (220/63) | 100.0 % | moderate | critical | moderate | crucial | 1 |
| deaths (time to event analysis only) | 0.75 [0.60, 0.93] | | < 1 | | 98% | 58 studies (40/18) | 99.5 % | moderate | critical | moderate | crucial | - |
| clinical deterioration | 0.80 [0.68, 0.93] | | < 1 | | 65% | 52 studies (42/10) | 99.8 % | moderate | low | moderate | important | - |
| clinical improvement | 1.17 [1.09, 1.26] | | > 1 | | 47% | 61 studies (58/3) | 100.0 % | moderate | critical | moderate | important | - |
| clinical improvement (14-day) | 1.17 [1.03, 1.33] | | > 1 | | 47% | 29 studies (29/-) | 99.3 % | some concern | low | moderate | important | - |
| clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
| clinical improvement (28-day) | 1.31 [1.14, 1.50] | | > 1 | | 45% | 23 studies (22/1) | 100.0 % | moderate | critical | moderate | important | - |
| clinical improvement (7-day) | 1.16 [1.00, 1.36] | | > 1 | | 47% | 20 studies (19/1) | 97.3 % | moderate | critical | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.14 [1.08, 1.21] | | > 1 | | 16% | 34 studies (33/1) | 100.0 % | moderate | critical | moderate | important | - |
| death or ventilation | 0.92 [0.88, 0.97] | | < 1 | | 53% | 43 studies (40/3) | 99.9 % | moderate | critical | moderate | important | - |
| hospital discharge | 1.07 [1.01, 1.13] | | > 1 | | 71% | 42 studies (36/6) | 99.2 % | moderate | critical | moderate | important | - |
| hospitalization | 0.57 [0.22, 1.47] | | < 1 | | 81% | 5 studies (4/1) | 87.8 % | moderate | not evaluable | moderate | important | - |
| mechanical ventilation | 0.90 [0.83, 0.98] | | < 1 | | 33% | 70 studies (64/6) | 99.4 % | moderate | critical | moderate | important | 1 |
| mechanical ventilation (time to event analysis only) | 0.78 [0.51, 1.22] | | < 1 | | 26% | 7 studies (5/2) | 86.0 % | moderate | serious | moderate | important | - |
| radiologic improvement (14-day) | 2.13 [1.30, 3.50] | | > 1 | | 21% | 6 studies (6/-) | 99.9 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 0.40 [0.02, 6.97] | | > 1 | | 77% | 3 studies (3/-) | 26.9 % | some concern | not evaluable | moderate | important | - |
| Recovery (time to event analysis only) | 1.02 [0.81, 1.28] | | > 1 | | 0% | 1 study (1/-) | 56.7 % | NA | not evaluable | | important | - |
| viral clearance | 1.70 [1.27, 2.27] | | > 1 | | 76% | 27 studies (25/2) | 100.0 % | moderate | critical | moderate | important | - |
| viral clearance (time to event analysis only) | 1.11 [0.89, 1.38] | | > 1 | | 62% | 13 studies (9/4) | 82.7 % | moderate | critical | moderate | important | - |
| viral clearance by day 14 | 1.18 [0.70, 1.99] | | > 1 | | 90% | 20 studies (16/4) | 73.2 % | serious | low | low | important | - |
| viral clearance by day 7 | 1.23 [1.00, 1.52] | | > 1 | | 63% | 17 studies (17/-) | 97.2 % | some concern | low | moderate | important | - |
| ICU admission | 0.75 [0.62, 0.90] | | < 1 | | 46% | 41 studies (35/6) | 99.9 % | moderate | critical | moderate | non important | - |
| Major thrombotic events or death | 1.04 [0.80, 1.36] | | < 1 | | 0% | 1 study (1/-) | 38.7 % | NA | not evaluable | | non important | - |
| off oxygenation | 1.39 [0.29, 6.74] | | > 1 | | 70% | 3 studies (3/-) | 65.7 % | high | not evaluable | low | non important | - |
| recovery | 1.12 [1.01, 1.23] | | > 1 | | 33% | 14 studies (14/-) | 98.6 % | some concern | critical | moderate | non important | - |
safety endpoints 00 |
| AE leading to drug discontinuation | 2.43 [0.79, 7.45] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | important | - |
| cardiac arrest | 1.91 [1.01, 3.62] | | < 1 | | 0% | 2 studies (1/1) | 2.3 % | serious | not evaluable | low | important | - |
| composite safety outcome | 1.56 [0.78, 3.11] | | < 1 | | 0% | 1 study (1/-) | 10.3 % | NA | not evaluable | | important | - |
| related AE (TRAE) | 1.26 [0.14, 11.07] | | < 1 | | 0% | 2 studies (2/-) | 41.9 % | some concern | not evaluable | moderate | important | - |
| related SAE (TRSAE) | 1.24 [0.50, 3.11] | | < 1 | | 0% | 1 study (1/-) | 32.0 % | NA | not evaluable | | important | - |
| serious adverse events | 1.00 [0.89, 1.12] | | < 1 | | 14% | 50 studies (50/-) | 51.9 % | some concern | low | moderate | important | - |
| superinfection | 1.17 [0.66, 2.07] | | < 1 | | 80% | 7 studies (5/2) | 29.5 % | moderate | not evaluable | moderate | important | - |
| abnormal ECG findings | 1.50 [0.88, 2.57] | | < 1 | | 0% | 1 study (-/1) | 7.0 % | NA | not evaluable | | non important | - |
| acute kidney injury | 0.74 [0.28, 1.99] | | < 1 | | 42% | 2 studies (1/1) | 72.4 % | low | not evaluable | high | non important | - |
| adverse events | 1.49 [1.26, 1.76] | | < 1 | | 52% | 45 studies (45/-) | 0.0 % | some concern | critical | moderate | non important | - |
| arrhythmia | 1.00 [0.55, 1.84] | | < 1 | | 55% | 5 studies (3/2) | 49.6 % | moderate | not evaluable | moderate | non important | - |
| cardiovascular or renal events | 1.87 [1.25, 2.80] | | < 1 | | 0% | 1 study (-/1) | 0.1 % | NA | not evaluable | | non important | - |
| deep vein thrombosis | 0.62 [0.23, 1.64] | | < 1 | | 0% | 2 studies (2/-) | 83.1 % | some concern | not evaluable | moderate | non important | - |
| elevated liver enzymes | 0.83 [0.33, 2.05] | | < 1 | | 77% | 4 studies (3/1) | 65.9 % | low | not evaluable | high | non important | - |
| hyperbilirubinemia | 0.97 [0.48, 1.93] | | < 1 | | 0% | 2 studies (2/-) | 53.8 % | low | not evaluable | high | non important | - |
| long QT | 2.39 [0.24, 23.87] | | < 1 | | 80% | 2 studies (2/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
| Major bleeding | 1.75 [1.14, 2.69] | | < 1 | | 0% | 4 studies (4/-) | 0.5 % | some concern | not evaluable | moderate | non important | - |
| Myocardial infarction | 0.87 [0.19, 3.92] | | < 1 | | 0% | 1 study (-/1) | 57.2 % | NA | not evaluable | | non important | - |
| pulmonary embolism | 0.82 [0.20, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| renal impairment | 1.26 [0.95, 1.67] | | < 1 | | 0% | 4 studies (4/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
| severe adverse events | 1.10 [0.07, 18.09] | | < 1 | | 0% | 2 studies (2/-) | 47.4 % | high | not evaluable | low | non important | - |
| venous thromboembolism | 5.23 [0.42, 65.62] | | < 1 | | 0% | 1 study (-/1) | 10.2 % | NA | not evaluable | | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.96 [0.73, 1.27] | | < 1 | | 0% | 3 studies (3/-) | 60.5 % | some concern | not evaluable | moderate | non important | - |
